76.22
0.31 (0.41%)
Market Trend
Short Term | Medium Term | ||
Industry | Medical Instruments & Supplies (US) | Bearish | Bearish |
Medical Instruments & Supplies (Global) | Mixed | Bearish | |
Stock | Hologic, Inc. | Bullish | Bullish |
Analyst Consensus
4 Buy, 1 Hold
Avg. Price @ Call: 76.73
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts. |
|
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Investment Style | Mid Core |
52 Weeks Range |
64.02 - 86.74
|
|
Price Target Range | ||
High | 95.00 (Argus Research, 24.64%) | Buy |
95.00 (Citigroup, 24.64%) | Buy | |
Median | 91.00 (19.39%) | |
Low | 78.00 (Evercore ISI Group, 2.34%) | Hold |
Average | 89.80 (17.82%) | |
Total | 4 Buy, 1 Hold |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Argus Research | 09 May 2024 | 95.00 (24.64%) | Buy | 75.75 |
JP Morgan | 03 May 2024 | 91.00 (19.39%) | Buy | 76.54 |
Needham | 03 May 2024 | 90.00 (18.08%) | Buy | 76.54 |
10 Apr 2024 | 90.00 (18.08%) | Buy | 77.61 | |
Evercore ISI Group | 04 Apr 2024 | 78.00 (2.34%) | Hold | 77.28 |
Citigroup | 03 Apr 2024 | 95.00 (24.64%) | Buy | 77.53 |
No data within this time range.
Date | Type | Details |
---|---|---|
02 May 2024 | Announcement | Hologic Announces Financial Results for Second Quarter of Fiscal 2024 |
29 Apr 2024 | Announcement | Hologic to Acquire Endomagnetics Ltd, a Breast Surgical Guidance Company |
11 Apr 2024 | Announcement | Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography |
02 Apr 2024 | Announcement | Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024 |
05 Mar 2024 | Announcement | Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing |
27 Feb 2024 | Announcement | Hologic to Unveil Groundbreaking AI Research at ECR 2024 |
26 Feb 2024 | Announcement | Hologic to Webcast Presentations at Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |